Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Does rosiglitazone adversely affect bone formation and bone mineral density in postmenopausal women?

Nature Clinical Practice Endocrinology & Metabolism volume 3, pages 622–623 (2007)Cite this article

boxed-textGrey A et al. (2007) The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 92: 1305–1310

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Rzonca SO et al. (2004) Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 145: 401–406

    Article  CAS  Google Scholar 

  2. Kahn SE et al. (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355: 2427–2443

    Article  CAS  Google Scholar 

  3. Takeda Pharmaceuticals letter to healthcare providers [www.fda.gov/medwatch/safety/2007/Actosmar0807.pdf] (accessed 4 May 2007).

  4. Schwartz AV et al. (2006) Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 91: 3349–3354

    Article  CAS  Google Scholar 

  5. Hangartner TN and Johnston CC (1990) Influence of fat on bone measurements with dual-energy absorptiometry. Bone Miner 9: 71–81

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Vicky Heath, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. AV Schwartz is an Assistant Professor in the Department of Epidemiology and Biostatistics, University of California San Francisco, CA, USA.,

    Ann V Schwartz

  2. SR Cummings is a Senior Scientist in the California Pacific Medical Center Research Institute, San Francisco, CA, USA.,

    Steven R Cummings

Authors
  1. Ann V Schwartz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Steven R Cummings
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ann V Schwartz.

Ethics declarations

Competing interests

AV Schwartz is a consultant for GlaxoSmithKline. SR Cummings declared he has no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schwartz, A., Cummings, S. Does rosiglitazone adversely affect bone formation and bone mineral density in postmenopausal women?. Nat Rev Endocrinol 3, 622–623 (2007). https://doi.org/10.1038/ncpendmet0562

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpendmet0562

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing